Success Metrics

Clinical Success Rate
84.4%

Based on 602 completed trials

Completion Rate
84%(602/713)
Active Trials
261(21%)
Results Posted
41%(247 trials)
Terminated
111(9%)

Phase Distribution

Ph not_applicable
691
56%
Ph phase_4
85
7%
Ph early_phase_1
8
1%
Ph phase_3
130
10%
Ph phase_2
180
14%
Ph phase_1
43
3%

Phase Distribution

51

Early Stage

180

Mid Stage

215

Late Stage

Phase Distribution1137 total trials
Early Phase 1First-in-human
8(0.7%)
Phase 1Safety & dosage
43(3.8%)
Phase 2Efficacy & side effects
180(15.8%)
Phase 3Large-scale testing
130(11.4%)
Phase 4Post-market surveillance
85(7.5%)
N/ANon-phased studies
691(60.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.2%

602 of 780 finished

Non-Completion Rate

22.8%

178 ended early

Currently Active

261

trials recruiting

Total Trials

1,245

all time

Status Distribution
Active(350)
Completed(602)
Terminated(178)
Other(115)

Detailed Status

Completed602
Recruiting202
unknown113
Terminated111
Not yet recruiting73
Withdrawn67

Development Timeline

Analytics

Development Status

Total Trials
1245
Active
261
Success Rate
84.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (0.7%)
Phase 143 (3.8%)
Phase 2180 (15.8%)
Phase 3130 (11.4%)
Phase 485 (7.5%)
N/A691 (60.8%)

Trials by Status

recruiting20216%
suspended20%
active_not_recruiting595%
unknown1139%
not_yet_recruiting736%
terminated1119%
completed60248%
enrolling_by_invitation161%
withdrawn675%

Recent Activity

Clinical Trials (1,245)

Showing 20 of 1,245 trialsScroll for more
NCT04048772Not Applicable

CALM IVF (Creating Affiliations, Learning, and Mindfulness for In Vitro Fertilization Patients)

Completed
NCT07158736Not Applicable

Genicular Nerve Block for Knee Pain in the ED

Completed
NCT07155187Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT04751435Not Applicable

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Recruiting
NCT07078968

A Real World Data Collection of Human Amniotic Membrane(s) on Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers and Post Operative Wounds

Completed
NCT07819084Not Applicable

Shockwave Therapy on Treating Erectile Dysfunction Following Nerve-sparing Radical Prostatectomy.

Not Yet Recruiting
NCT06428838Phase 3

Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Enrolling By Invitation
NCT07782996Phase 3

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)

Recruiting
NCT05799664Not Applicable

Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD

Recruiting
NCT03596450Phase 4

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Completed
NCT06072482Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting
NCT05685004Phase 2

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Active Not Recruiting
NCT07096726Not Applicable

Boston Medical Center Ultrasound Decongestion Study in Heart Failure

Not Yet Recruiting
NCT04405401Phase 2

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Terminated
NCT03623464Not Applicable

RCT of Mobile Apps & FitBit v. Usual Care

Suspended
NCT05982769Not Applicable

Molecular Mechanism of Exercise in Cirrhosis

Recruiting
NCT07780656Phase 3

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)

Recruiting
NCT04096014Not Applicable

Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

Recruiting
NCT07780643Phase 3

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)

Recruiting
NCT07194070

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
1,245